ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Questioning the evidence behind the Saturation Model for TRT in prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 184427" data-attributes="member: 13851"><p><strong><span style="color: rgb(184, 49, 47)">Letter to the editor:</span> Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer</strong></p><p></p><p><span style="color: rgb(184, 49, 47)">Abraham Morgentaler , Abdulmaged M. Traish</span></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>To the editor: </strong></span></p><p><span style="color: rgb(0, 0, 0)"></span></p><p><span style="color: rgb(0, 0, 0)">We are honored by Dr. Kim’s detailed review [1] of our paper, titled, </span><span style="color: rgb(184, 49, 47)"><em>“Shifting the paradigm of testosterone and prostate cancer: The Saturation Model and the limits of androgen-dependent growth,” [2]</em></span><span style="color: rgb(0, 0, 0)"> and grateful for his generous comments. However, we feel obligated to address several inaccurate comments by Dr. Kim. </span></p><p><span style="color: rgb(0, 0, 0)"></span></p><p><span style="color: rgb(0, 0, 0)">It has now been 11 years since the publication of this article, and over that time we have been gratified by the wealth of published research confirming all key elements of the Saturation Model. </span><span style="color: rgb(184, 49, 47)"><em>The introduction of the Saturation Model revolutionized concepts regarding the relationship of androgens and prostate growth, benign and malignant, and has served as the theoretical framework for major changes in clinical practice, including the use of testosterone (T) therapy in men with prostate cancer (PCa).</em></span> <span style="color: rgb(44, 130, 201)"><em>It is important for younger readers to understand that, prior to the introduction of the Saturation Model, the universally held belief was the “Androgen Hypothesis”, which held that higher androgen concentrations caused proportionally greater growth of prostate tissue and that higher serum T meant greater PCa risk and aggressiveness.</em></span></p><p></p><p><em><span style="color: rgb(184, 49, 47)">The saturation model provided a radically different view, one that resolved an awkward paradox in which androgen deprivation clearly lowered prostate-specific antigen (PSA), yet raising T in hormonally intact men had little effect on PSA or prostate size. </span></em>In one swoop, the Saturation Model assembled a messy assortment of clinical observations and experimental results into a coherent picture. <span style="color: rgb(184, 49, 47)"><strong><em>Simply, the Saturation Model holds that prostate tissue is exquisitely sensitive to changes in serum androgens at low concentrations,</em></strong></span> <span style="color: rgb(44, 130, 201)"><em><strong>and little to no sensitivity once a saturation point is reached. Clinical data indicate the saturation point for serum T is approximately 250 ng/dL [3-5].</strong></em></span></p><p></p><p>The mechanisms underlying the Saturation Model include the following observations:<span style="color: rgb(184, 49, 47)"> <em><strong>a)</strong></em></span><span style="color: rgb(0, 0, 0)"><em><strong> T or its derivative, 5α-dihydrotestosterone (5α-DHT), mediate prostatic cellular function by binding to the androgen receptors (AR). </strong></em></span><span style="color: rgb(184, 49, 47)"><em><strong>b) </strong></em></span><span style="color: rgb(0, 0, 0)"><em><strong>There is a finite number of AR binding sites per cell, and</strong></em></span><span style="color: rgb(184, 49, 47)"><em><strong> c) </strong></em></span><span style="color: rgb(0, 0, 0)"><em><strong>once AR sites are fully occupied with T or 5α-DHT, <u>a saturation state is achieved, beyond which increasing circulating T or 5α-DHT cannot elicit additional biological activity via this mechanism</u> [2].</strong></em></span> Other mechanisms are possible [6], yet this relationship of androgens with AR is adequate to explain observed phenomena over a wide range of experimental data.</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><em><span style="color: rgb(184, 49, 47)">More than a decade since its publication, the Saturation Model has turned out to be a robust description of the relationship between androgens and the prostate, and we are unaware of any compelling evidence to the contrary.</span></em></strong><span style="color: rgb(44, 130, 201)"> <strong><em>At this point, we conclude that the Saturation Model should no longer be considered a hypothesis, but rather an accurate framework describing the relationship of androgens and the prostate. </em></strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 184427, member: 13851"] [B][COLOR=rgb(184, 49, 47)]Letter to the editor:[/COLOR] Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer[/B] [COLOR=rgb(184, 49, 47)]Abraham Morgentaler , Abdulmaged M. Traish[/COLOR] [COLOR=rgb(0, 0, 0)][B]To the editor: [/B] We are honored by Dr. Kim’s detailed review [1] of our paper, titled, [/COLOR][COLOR=rgb(184, 49, 47)][I]“Shifting the paradigm of testosterone and prostate cancer: The Saturation Model and the limits of androgen-dependent growth,” [2][/I][/COLOR][COLOR=rgb(0, 0, 0)] and grateful for his generous comments. However, we feel obligated to address several inaccurate comments by Dr. Kim. It has now been 11 years since the publication of this article, and over that time we have been gratified by the wealth of published research confirming all key elements of the Saturation Model. [/COLOR][COLOR=rgb(184, 49, 47)][I]The introduction of the Saturation Model revolutionized concepts regarding the relationship of androgens and prostate growth, benign and malignant, and has served as the theoretical framework for major changes in clinical practice, including the use of testosterone (T) therapy in men with prostate cancer (PCa).[/I][/COLOR] [COLOR=rgb(44, 130, 201)][I]It is important for younger readers to understand that, prior to the introduction of the Saturation Model, the universally held belief was the “Androgen Hypothesis”, which held that higher androgen concentrations caused proportionally greater growth of prostate tissue and that higher serum T meant greater PCa risk and aggressiveness.[/I][/COLOR] [I][COLOR=rgb(184, 49, 47)]The saturation model provided a radically different view, one that resolved an awkward paradox in which androgen deprivation clearly lowered prostate-specific antigen (PSA), yet raising T in hormonally intact men had little effect on PSA or prostate size. [/COLOR][/I]In one swoop, the Saturation Model assembled a messy assortment of clinical observations and experimental results into a coherent picture. [COLOR=rgb(184, 49, 47)][B][I]Simply, the Saturation Model holds that prostate tissue is exquisitely sensitive to changes in serum androgens at low concentrations,[/I][/B][/COLOR] [COLOR=rgb(44, 130, 201)][I][B]and little to no sensitivity once a saturation point is reached. Clinical data indicate the saturation point for serum T is approximately 250 ng/dL [3-5].[/B][/I][/COLOR] The mechanisms underlying the Saturation Model include the following observations:[COLOR=rgb(184, 49, 47)] [I][B]a)[/B][/I][/COLOR][COLOR=rgb(0, 0, 0)][I][B] T or its derivative, 5α-dihydrotestosterone (5α-DHT), mediate prostatic cellular function by binding to the androgen receptors (AR). [/B][/I][/COLOR][COLOR=rgb(184, 49, 47)][I][B]b) [/B][/I][/COLOR][COLOR=rgb(0, 0, 0)][I][B]There is a finite number of AR binding sites per cell, and[/B][/I][/COLOR][COLOR=rgb(184, 49, 47)][I][B] c) [/B][/I][/COLOR][COLOR=rgb(0, 0, 0)][I][B]once AR sites are fully occupied with T or 5α-DHT, [U]a saturation state is achieved, beyond which increasing circulating T or 5α-DHT cannot elicit additional biological activity via this mechanism[/U] [2].[/B][/I][/COLOR] Other mechanisms are possible [6], yet this relationship of androgens with AR is adequate to explain observed phenomena over a wide range of experimental data. [B][I][COLOR=rgb(184, 49, 47)]More than a decade since its publication, the Saturation Model has turned out to be a robust description of the relationship between androgens and the prostate, and we are unaware of any compelling evidence to the contrary.[/COLOR][/I][/B][COLOR=rgb(44, 130, 201)] [B][I]At this point, we conclude that the Saturation Model should no longer be considered a hypothesis, but rather an accurate framework describing the relationship of androgens and the prostate. [/I][/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Questioning the evidence behind the Saturation Model for TRT in prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top